Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.
BACKGROUND
Despite the beneficial effect of imatinib treatment in chronic myeloid leukemia patients, some patients develop resistance and/or intolerance and need a switch to second-generation tyrosine kinase inhibitors. Dasatinib is indicated for chronic myeloid leukemia patients with resistance or intolerance to imatinib; it has 325-fold increase potency compared to imatinib and is active in mutated and unmutated resistant patients. Pleural/pericardic effusions are frequent complications during treatment with dasatinib, and usually are reported to require dose reduction or drug discontinuation. Changing the dasatinib regimen from 70 mg twice daily to 100 mg once daily reduces the risk of pleural effusions.


METHODS
In this article, we review the incidence of the phenomenon observed in different dasatinib trials (Phase I - III) and the currently suggested management. We also describe the identified pathogenetic mechanisms related to the development and discuss the associated risk factors.


RESULTS
The aim of this paper is to provide healthcare professionals with clear guidance on the management of pleural effusions associated with dasatinib treatment. Recommendations are based on the published data and clinical experience from a number of different centers.


CONCLUSIONS
Literature evidences support the fact that with adequate management and monitoring of patients with predisposing factors, pleural effusions can be easily managed.
Breccia
Massimo
M
Sapienza University, Department of Cellular Biotechnologies and Hematology, Via Benevento 6, 00161, Rome, Italy. breccia@bce.uniroma1.it
Alimena
Giuliana
G
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000453:epidemiology; D001549:Benzamides; D002318:Cardiovascular Diseases / Q000453:epidemiology; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015897:Comorbidity; D000069439:Dasatinib; D019468:Disease Management; D004334:Drug Administration Schedule; D003875:Drug Eruptions / Q000209:etiology; D006801:Humans; D006937:Hypercholesterolemia / Q000453:epidemiology; D000068877:Imatinib Mesylate; D015994:Incidence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000453:epidemiology; D007958:Leukocyte Count; D010490:Pericardial Effusion / Q000139:chemically induced* / Q000453:epidemiology; D010879:Piperazines / Q000009:adverse effects; D010996:Pleural Effusion / Q000139:chemically induced* / Q000453:epidemiology; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D000069439:Dasatinib